No.	Recommendation	GoR	LoE	Sources
3.3	A reduction in the risk of endometrial cancer was observed for women who received continuous combined hormone therapy with conjugated equine estrogens and medroxyprogesterone acetate as the progestogen over an average period of 5.6 years.	ST	2	12
3.3.1	Continuous combined hormone therapy administered for < 5 years may be considered safe with regard to the risk of developing endometrial cancer.	ST	2	6 ,  7 ,  9 ,  10 ,  12 ,  13 ,  14